OraSure rises after launch of OraQuick In-Home HIV test for U.S. consumers OraSure is trading up over 5.6% at time of writing following news yesterday that the company's OraQuick In-Home HIV test is now available to U.S. consumers at retailers nationwide and online. Resistance is at $11.02. Support is at $10.71.
News For OSUR From The Last 14 Days
Check below for free stories on OSUR the last two weeks.